Taiho Pharmaceutical Co., Ltd. (TPC), Japan, part of Otsuka Holdings, established its Canadian affiliate in 2017. Ross Glover, general manager for Taiho Pharma Canada, has spent the past year tackling the mammoth task of establishing the foundations for the operations, including preparing a new drug for market approval and navigating the complex healthcare landscape in Canada.
Could you outline the rationale behind why 2017 was the right time to introduce Taiho Pharma to Canada?
"We advocate with facts: we show what the potential costs are, we use academics' past achievements in Canada, and we show how advances and progress made here are communicated and accepted globally."
